Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label, Parallel Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of LuminoMark Inj. Versus Charcotrace Inj. in Patients With Nonpalpable Breast Lesions

NCT04606329 is registered in ClinicalTrials.gov with Hanlim Pharm. Co., Ltd. as lead sponsor.

NCT NCT04606329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04606329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label, Parallel Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of LuminoMark Inj. Versus Charcotrace Inj. in Patients With Nonpalpable Breast Lesions
Lead sponsor
Hanlim Pharm. Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
July 20, 2020
Completion date
January 28, 2021
Enrollment
109 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast diseases